Refreshing results…
Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
UploadCurrent Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
Download from doi.orgCutting-Edge CAR Engineering: Beyond T Cells
Download from doi.orgSystemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
Download from doi.orgCutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
Download from doi.orgCAR-T Cells for the Treatment of Lung Cancer
Download from doi.orgMissing publications? Search for publications with a matching author name.